Mineralys Drug Sustains Blood Pressure Gains Ahead of FDA Decision
RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) reported that its experimental hypertension drug lorundrostat sustained a 17.8 mmHg reduction in systolic blood pressure through 48 weeks, providing additional long-term …
Mineralys Drug Sustains Blood Pressure Gains Ahead of FDA Decision Read More